Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer

Serial immunological parameters in a phase II trial of exemestane and low-dose oral... Breast Cancer Res Treat (2018) 168:57–67 https://doi.org/10.1007/s10549-017-4570-4 CLINICAL TRIAL Serial immunological parameters in a phase II trial of exemestane and low‑dose oral cyclophosphamide in advanced hormone receptor‑positive breast cancer 1 1 1 1 2 1 1 Maryann Kwa  · Xiaochun Li  · Yelena Novik  · Ruth Oratz  · Komal Jhaveri  · Jennifer Wu  · Ping Gu  · 1 1 1 1 1 3 Marleen Meyers  · Franco Muggia  · James Speyer  · Alyssa Iwano  · Maryam Bonakdar  · Lina Kozhaya  · 1 1 1 1 1,3 1 Ece Tavukcuoglu  · Bahar Budan  · Roy Raad  · Judith D. Goldberg  · Derya Unutmaz  · Sylvia Adams   Received: 18 October 2017 / Accepted: 4 November 2017 / Published online: 9 November 2017 © Springer Science+Business Media, LLC, part of Springer Nature 2017 Abstract responses were seen in 6/23 patients (26.1%; 95% CI 10.2– Background and purpose Resistance to endocrine thera- 48.4%) and were durable (median 11.6  months). Three- pies in hormone receptor (HR)-positive breast cancer is a month PFS rate was 50.1% (95% CI 33.0–76.0%); median significant challenge. Prior studies have shown that low-dose PFS was 4.23 months (95% CI 2.8–11.7). No treatment- oral cyclophosphamide can transiently deplete regulatory T related decrease in Tregs was observed. However, elevated cells (Tregs) and improve anti-tumor immunity. We inves- baseline levels of Naïve Tregs [greater than 2.5 (the median http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Breast Cancer Research and Treatment Springer Journals

Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer

Loading next page...
 
/lp/springer_journal/serial-immunological-parameters-in-a-phase-ii-trial-of-exemestane-and-YqEyVSpiQ4
Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer Science+Business Media, LLC, part of Springer Nature
Subject
Medicine & Public Health; Oncology
ISSN
0167-6806
eISSN
1573-7217
D.O.I.
10.1007/s10549-017-4570-4
Publisher site
See Article on Publisher Site

Abstract

Breast Cancer Res Treat (2018) 168:57–67 https://doi.org/10.1007/s10549-017-4570-4 CLINICAL TRIAL Serial immunological parameters in a phase II trial of exemestane and low‑dose oral cyclophosphamide in advanced hormone receptor‑positive breast cancer 1 1 1 1 2 1 1 Maryann Kwa  · Xiaochun Li  · Yelena Novik  · Ruth Oratz  · Komal Jhaveri  · Jennifer Wu  · Ping Gu  · 1 1 1 1 1 3 Marleen Meyers  · Franco Muggia  · James Speyer  · Alyssa Iwano  · Maryam Bonakdar  · Lina Kozhaya  · 1 1 1 1 1,3 1 Ece Tavukcuoglu  · Bahar Budan  · Roy Raad  · Judith D. Goldberg  · Derya Unutmaz  · Sylvia Adams   Received: 18 October 2017 / Accepted: 4 November 2017 / Published online: 9 November 2017 © Springer Science+Business Media, LLC, part of Springer Nature 2017 Abstract responses were seen in 6/23 patients (26.1%; 95% CI 10.2– Background and purpose Resistance to endocrine thera- 48.4%) and were durable (median 11.6  months). Three- pies in hormone receptor (HR)-positive breast cancer is a month PFS rate was 50.1% (95% CI 33.0–76.0%); median significant challenge. Prior studies have shown that low-dose PFS was 4.23 months (95% CI 2.8–11.7). No treatment- oral cyclophosphamide can transiently deplete regulatory T related decrease in Tregs was observed. However, elevated cells (Tregs) and improve anti-tumor immunity. We inves- baseline levels of Naïve Tregs [greater than 2.5 (the median

Journal

Breast Cancer Research and TreatmentSpringer Journals

Published: Nov 9, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off